Smoking Cessation Program for the Elderly
Launched by THE UNIVERSITY OF HONG KONG · Jan 22, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a program to help older adults quit smoking, specifically focusing on those aged 60 and above in Hong Kong. The program will use mobile health technology, like text messages and instant messaging, as well as financial incentives to encourage participants to stop smoking. Researchers want to see how effective these methods are in helping elderly smokers succeed in quitting.
To participate, individuals must be at least 60 years old, have been smoking regularly for the past three months, and live in Hong Kong. They also need to have a mobile phone capable of receiving messages and earn less than the average income for households in the area. Participants can expect to receive support through their phones, which may help keep them motivated to quit smoking. It's important to note that smokers who are currently using other quit-smoking services or who are in the hospital cannot join this trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Smokers aged 60 years or above;
- • 2. Currently smoking cigarettes or alternative tobacco products daily in the past 3 months with an exhaled carbon monoxide (CO) level ≥4ppm or salivary cotinine \>30 ng/ml;
- • 3. Have a mobile phone that can receive short message/messaging Service (SMS) or instant messages (IM);
- • 4. Having a household monthly income lower than the median income of domestic household in Hong Kong
- • 6. Hong Kong residents able to communicate in Chinese.
- Exclusion Criteria:
- • 1. Smokers not physically nor mentally fit for communication;
- • 2. Smokers currently using SC services;
- • 3. Hospitalized smokers;
- • 4. Not having a mobile phone or perceived difficulty in using mobile phone or communication Apps
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported